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OBJECTIVES: The study objective was to assess costs and the
cost effectiveness of early and late epoetin administration in
chronic renal insufﬁciency during the predialysis period in
Poland. METHODS: The analysis was based on clinical data
from systematic literature review. Only direct medical costs were
included into the study. The effectiveness was expressed as death
or dialysis avoided. The cost-effectiveness analysis from the
payer perspective was conducted. RESULTS: The mean individ-
ual treatment cost of early and late epoetin administration in
chronic renal insufﬁciency during the predialysis period was esti-
mated for €3597 (1 € = 4.035 PLN) and €2163, respectively. The
cost of death or dialysis avoided in the early and late introduced
epoetin treatment amounted to €5058 and €4429, respectively.
However 14% increment of this equation in patients early
treated with epoetin resulted in over 50% decrement of end point
appearance (initiation of dialysis or death). CONCLUSIONS:
For the majority of patients early treatment with epoetin trans-
lates into signiﬁcant delay of renal replacement therapy. Early
introduction of epoetin treatment in chronic renal insufﬁciency
patients before dialysis is cost-effective.
PUK6
COST-EFFECTIVENESS OF TREATMENT WITH EPOIETIN
ALPHA FOR PATIENTS WITH ANAEMIA DUE TO RENAL
FAILURE—THE CASE OF SWEDEN
Glenngård AH1, Schön S2, Persson U3
1The Swedish Institute for Health Economics, IHE, Lund, Sweden,
2Ryhov County Hospital, Jönköping, Sweden, 3The Swedish Institute
for Health conomics, IHE, Lund, Sweden
Anaemia is a common complication of renal failure. Anaemia
can be treated with erythropoietin (EPO) administration, RBC
transfusion, or a combination of both. EPO has been registered
for treatment of renal anaemia in Sweden since the beginning of
the 1990s, and is the primary treatment regimen for anaemia
related to renal failure. OBJECTIVE: The objective of this study
was to carry out a cost-effectiveness analysis of treatment with
epoietin alpha compared to treatment with RBC transfusion for
patients with anaemia associated with renal failure in Sweden.
METHOD: Incremental costs associated with EPO treatment
compared with the traditional treatment therapy of blood trans-
fusion (costs of EPO, iron supplementation, administration and
surveillance, EPO complications and costs of blood transfusion)
are estimated. Swedish treatment guidelines, patient characteris-
tics and unit costs (provider perspective) are used throughout the
study. Information about QALY gains is collected from the lit-
erature. RESULTS: The estimated cost per QALY gained from
administration of EPO to renal patients in Sweden was found to
be SEK 403,921 (EUR 43,201) on average. The cost of treatment
with EPO differs widely between haemodialysis (HD) and peri-
tonealdialysis (PD) patients due to different dosages of EPO and
iron supplementation. The results were found to be sensitive
regarding assumptions on QALY gains but not regarding the cost
of blood transfusion. CONCLUSION: The estimated cost per
QALY falls within the range acceptable of the value of a QALY
in Sweden for both HD and PD patients. EPO administration to
renal patients is much more costly in Sweden than in the UK,
primarily due to higher dosage of EPO and iron supplementa-
tion in Sweden. Swedish patients, on the other hand reach higher
Hb-levels than patients in the UK.
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Benign prostatic hyperplasia (BPH) is common in older men
affecting 40% of men in their ﬁfties. If the enlarged gland begins
to press upon the urethra and to interfere with urination, then
treatment may be needed. Transurethral resection of the prostate
(TURP) is a minimally invasive treatment that has became the
gold standard for patients who are unwilling to remain on med-
ication or in whom medical therapy failed. Recently a minimally
invasive surgery treatment has shown similar results compared
to TURP, transurethral needle ablation of the prostate (PROS-
TIVA®). OBJECTIVES: To carry out an economic evaluation of
PROSTIVA® vs. TURP in non-drug respondent BHP patients in
the Spanish setting. METHODS: A Markov model was devel-
oped in order to simulate the clinical and economical conse-
quences of using PROSTIVA® or TURP in BHP. Four health
states were considered: Intervention, therapeutic success, non-
therapeutic success and permanent adverse events through a
cost-effectiveness analysis. Clinical and economical data were
retrieved from published clinical trials and validated by a clini-
cian experienced in the BHP management. Perspective of the
analysis was the National Health System perspective, so only
direct costs were included. The time horizon was 15 years with
6 months cycles, so clinical and economical results were dis-
counted at a 3% per year. A probabilistic sensitivity analysis
(PSA) was performed in order to check the variability in the
model results. All uncertain variables included were included in
PSA. RESULTS: Mean cost per patient with PROSTIVA® was
€1207 (p = 0.00) less than patients treated with TURP, but with
a decrement 0.42 QALYs (p = 0.00), which leads us to an ICER
of €2860/QALYs. Sensitivity analyses have shown consistent
results across changes in all variables. CONCLUSION: PROS-
TIVA® compared to TURP has shown to be an efﬁcient therapy
for non-drug respondents BHP patients in Spain, with an ICER
below accepted thresholds.
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BPH and associated lower urinary tract symptoms affect quality
of life of older men and could require surgery. The MTOPS study
demonstrated that the risk of overall clinical progression (includ-
ing worsening of symptoms, acute urinary retention, urinary
incontinence, renal insufﬁciency, or recurrent urinary infection)
was signiﬁcantly reduced by ﬁnasteride (−34%, p = 0.002), dox-
azosin (−39%, p < 0.001) and by the combination of both 
(−66%, p < 0.001), as compared with placebo. The clinical
beneﬁt of the combination was signiﬁcantly higher than the one
of each individual component. MTOPS study showed also that
only ﬁnasteride, alone or in combination with doxazosin reduced
signiﬁcantly (p < 0.001) the risk of invasive therapy by respec-
tively 64% and 67% compared with placebo. OBJECTIVE: To
estimate the cost-efﬁcacy of ﬁnasteride, doxazosin, and the com-
bination of both in the treatment of BPH in the perspective of
